Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Drugs In Development, 2022, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.
Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 8, 4 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
- The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycythemia Vera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycythemia Vera - Companies Involved in Therapeutics Development
Polycythemia Vera - Drug Profiles
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Mar 02, 2022: NCCN clinical practice guidelines in oncology update recommends BESREMi (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera
Feb 15, 2022: German Federal Court of Justice upholds AOP's license rights in ropeginterferon and PEC's liability for damages
Dec 14, 2021: PharmaEssentia USA selects Veeva Data Cloud to support launch of novel therapy for rare, chronic blood cancer
Dec 12, 2021: Protagonist Therapeutics presents updated phase 2 rusfertide data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting
Dec 06, 2021: BESREMi (ropeginterferon alfa-2b-njft), FDA approved for treatment of polycythemia vera, available at Biologics by McKesson
Nov 18, 2021: BESREMi (ropeginterferon alfa-2b-njft) now approved for the treatment of adults with polycythemia vera
Nov 15, 2021: BESREMi (Ropeginterferon alfa-2b) approved by the US FDA
Nov 12, 2021: U.S. FDA approves BESREMi (ropeginterferon alfa-2b-njft) as the only interferon for adults with polycythemia vera
Nov 04, 2021: Protagonist Therapeutics announces updated data from phase 2 study of Rusfertide in polycythemia vera selected for oral presentations at the ASH 2021 Annual Meeting
Oct 11, 2021: FDA lifts hold on Protagonist’s rusfertide clinical studies
Sep 20, 2021: FDA puts Protagonist Therapeutics’ rusfertide on clinical hold
Sep 14, 2021: PPMX-T003: Announcement on initiation of phase I clinical trial in polycythemia vera patients
Aug 10, 2021: Protagonist Therapeutics announces resolution of contract dispute with Zealand Pharma
Jun 11, 2021: Protagonist Therapeutics announces updated phase 2 data supporting long-term efficacy of Rusfertide in polycythemia vera
Jun 07, 2021: Protagonist Therapeutics to host Investor Conference Call and webcast to discuss updated Phase 2 Rusfertide results in Polycythemia Vera as presented at EHA 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Polycythemia Vera, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Polycythemia Vera - Pipeline by AbbVie Inc, 2022
Polycythemia Vera - Pipeline by Ascentage Pharma Group International, 2022
Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Polycythemia Vera - Pipeline by Fujifilm Holdings Corp, 2022
Polycythemia Vera - Pipeline by Hangzhou Bensheng Pharmaceutical Co Ltd, 2022
Polycythemia Vera - Pipeline by Imago BioSciences Inc, 2022
Polycythemia Vera - Pipeline by Incyte Corp, 2022
Polycythemia Vera - Pipeline by IO Biotech Inc, 2022
Polycythemia Vera - Pipeline by Ionis Pharmaceuticals Inc, 2022
Polycythemia Vera - Pipeline by Italfarmaco SpA, 2022
Polycythemia Vera - Pipeline by Kartos Therapeutics Inc, 2022
Polycythemia Vera - Pipeline by Merganser Biotech Inc, 2022
Polycythemia Vera - Pipeline by PharmaEssentia Corp, 2022
Polycythemia Vera - Pipeline by Protagonist Therapeutics Inc, 2022
Polycythemia Vera - Pipeline by Shanghai Xunhe Pharmaceutical Technology Co Ltd, 2022
Polycythemia Vera - Pipeline by Silence Therapeutics Plc, 2022
Polycythemia Vera - Pipeline by Sino Biopharmaceutical Ltd, 2022
Polycythemia Vera - Dormant Projects, 2022
Polycythemia Vera - Discontinued Products, 2022
List of Figures
Number of Products under Development for Polycythemia Vera, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage Molecule Types, 2022
